[T.S.R:16063] Pfizer to sell insulin from Biocon-Why Not Buy The Pfizer stock?

Pfizer Inc. has agreed to pay an initial $200 million to the Indian biotechnology company Biocon Ltd. for the right to sell its insulin products.The world's biggest drugmaker by revenue also agreed to pay Biocon as much as $150 million more in development and regulatory milestone payments. The marketing and distribution margins that make upto 20 per cent of the product price at the retail level, go to the marketer...so this begets the question why BUY the Biocon stock? Why not the Pfizer stock? Pfizer ( PFE - news - people ), based in New York, said Monday the deal gives it exclusive rights to sell Biocon's insulin and generic version of several insulin products in most countries. Insulin is used in the treatment of diabetes. Biocon makes recombinant human insulin, as well as generic version of Sanofi-Aventis ( SNY - news - people ) SA's insulin Lantus, Novo Nordisk ( NVO - news - people ) AS's NovoLog, and Eli Lilly and Co. ( LLY - news - people )'s HumaLog. Its recombinant human insulin has been approved in 27 countries and is on sale in 23. Safe Harbor Statement: Some forward looking statements on projections, estimates, expectations & outlook are included to enable a better comprehension of the Company prospects. Actual results may, however, differ materially from those stated on account of factors such as changes in government regulations, tax regimes, economic developments within India and the countries within which the Company conducts its business, exchange rate and interest rate movements, impact of competing products and their pricing, product demand and supply constraints.   Nothing in this article is, or should be construed as, investment advice.

--
For Anything related with Stock market be Online at
http://www.niftyviews.com/
 
Get free updates on your mobile phone. Sms "Join TSR " and send to 09223492234
 
FOR TRIAL STOCK/NIFTY/OPTION CALLS
 
 
You received this message because you are subscribed to Google Group "STOCKRESEARCHER" group.
To post to this group, send an email to STOCKRESEARCHER@googlegroups.com
 
To unsubscribe email
Stockresearcher-unsubscribe@googlegroups.com
 
for more info visit
http://groups.google.com/group/STOCKRESEARCHER?hl=en-GB
.
This is Not a Spam Mail.
Disclaimer :-
"The opinions expressed by the members on this board are based on
their individual experience and perceptions and to share information
with other members with the best of intentions to help fellow members
in investment decisions as equity investment is a risky venture."